Acurx Pharmaceuticals


Acurx Pharmaceuticals is a publicly held clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. Their approach targets the DNA polymerase IIIC enzyme and their pipeline includes candidates targeting Gram-positive bacteria such as MRSA, VRE, and PRSP. The company is actively engaged in advancing its research and development efforts, with recent financial results and cash flow statements indicating ongoing operations and financing activities.

Industries

Pharmaceutical
Therapeutics
Biotechnology Research

Nr. of Employees

small (1-50)

Acurx Pharmaceuticals

Staten Island, New York, United States


Patents

Use of ibezapolstat to promote microbiome health

US-12036225-B2

View Details

DNA polymerase IIIC inhibitors and use thereof

US-11001592-B2

View Details

DNA polymerase IIIC inhibitors and use thereof

US-10836772-B2

View Details

DNA polymerase IIIC inhibitors and use thereof

US-10723741-B1

View Details

Selective antibacterials for clostridium difficile infections

US-8796292-B2

View Details

Products

Clinical-stage DNA polymerase IIIC inhibitor (clinical candidate)

A clinical-stage small-molecule antibiotic candidate designed to inhibit bacterial DNA polymerase IIIC/PolC for treatment of Clostridioides difficile infection and other Gram-positive infections.

Early-stage Gram-positive antibiotic candidate portfolio

Pipeline of discovery-stage small-molecule antibiotic candidates directed at Gram-positive bacteria including MRSA, VRE and Streptococcus species.

ACX-362E

Acurx's initial antibiotic product development candidate is a DNA polymerase inhibitor with a novel mechanism of action for oral treatment of Clostridium difficile Infections, or CDI.

ibezapolstat

A lead DNA pol IIIC inhibitor in clinical development for the oral treatment of acute and multiply-recurrent C. difficile infection.

ACX-375C

Acurx's second antibiotic program in the lead optimization stage of preclinical development, seeking to develop innovative, systemic Gram-positive selective spectrum (GPSS) bactericidal antibiotics targeting multi-drug resistant and sensitive Gram-positive bacterial pathogens.


Services

Sponsored research and collaborative agreements with academic and clinical partners to generate target validation, efficacy and microbiome data supporting development of antibiotic candidates.

Preparation and delivery of scientific posters, oral presentations and publications to communicate nonclinical and clinical study results to scientific and clinical audiences.

Expertise Areas

  • Enzyme-targeted antibiotic discovery
  • Preclinical microbiology and in vivo pharmacology against Gram-positive pathogens
  • Clinical trial management for anti-infectives (including Phase 2 randomized, double‑blind studies)
  • Microbiome sequencing and comparative analysis in drug development
  • Show More (6)

Key Technologies

  • Target-based small-molecule inhibitor discovery
  • In vitro antibacterial susceptibility assays
  • Preclinical animal infection models
  • Microbiome sequencing and comparative bioinformatics
  • Show More (4)

News & Updates


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.